Leukemia
Conditions
Keywords
relapsed leukemia, refractory leukemia
Brief summary
This is a Phase 1, open-label, dose escalation study of JVRS-100. The study will proceed in 2 stages to minimize the number of patients treated at doses substantially below the recommended phase 2 dose. In stage 1, an accelerated titration schema will be followed with one patient at each dose level. Stage 2 will commence after a dose limiting toxicity is observed in stage 1 or after the maximum dose for stage 1 is reached. Stage 2 will follow a modified Fibonacci schema with 3-6 subjects at each dose level until a recommended phase 2 dose is determined. The cohort will then be expanded to a maximum of 12 patients to more fully evaluate the recommended phase 2 dose.
Detailed description
This is a Phase 1, open-label, dose escalation study of JVRS-100. The study will proceed in 2 stages to minimize the number of patients treated at doses substantially below the recommended phase 2 dose. In stage 1, cohorts of three will be treated at each dose level however doses will be doubled from level to level. Stage 2 will commence after a dose limiting toxicity is observed in stage 1 or after the maximum dose for stage 1 is reached. Stage 2 will follow a modified Fibonacci schema with 3-6 subjects at each dose level until a recommended phase 2 dose is determined. The cohort will then be expanded to a maximum of 12 patients to more fully evaluate the recommended phase 2 dose. The Principal Investigator will assign dose level to be administered to all patients.
Interventions
DRUGJVRS-100
Level 1: 0.5 µg/Kg D1,8,15; Level 2: 1.0 µg/Kg D1,8,15; Level 3:2.0 µg/Kg 1,15; Level 4: 2.0 µg/Kg D1,8,15; Level 5: 4.0 µg/Kg D1,15
Sponsors
Milton S. Hershey Medical Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 18 years of age * Histologically or cytologically documented relapsed or refractory acute leukemia * Unlikely to benefit from standard therapy in the opinion of the investigator or refuse standard therapy * ECOG performance status 0-2 * Adequate renal and hepatic function * No hematologic criteria for WBC, Hbg or platelets * Negative virology screen for HIV, hepatitis B surface antigen & hepatitis C * Female patients of childbearing potential must have a negative serum pregnancy test * Male & female patients must agree to use a medically acceptable barrier and/or chemical contraceptive method during the study and for a minimum of 3 months afte the last dose of study treatment. * Patients post blood or marrow transplant should demonstrate a circulating CD8 count of at lest 200 cells/ul
Exclusion criteria
* Active CNS leukemia * Current concomitant chemotherapy, radiation therapy or immunotherapy * Receipt of any investigational agent within 28 days of first dose of JVRS-100 * Persistent clinically significant toxicity from prior anticancer therapy that is \> Grade 2 (NCI CTCAE v3.0) * Bone marrow or stem cell transplant within 3 months prior to first dose of JVRS-100 * Chronic administration of immunosuppressive agents within 14 days of first dose of JVRS-100. Use of inhaled steroids, nasal sprays, eye drops, and topical creams for small body areas is allowed. * Pregnant or lactating * History of prior malignancy other than leukemia within the past 5 years, excluding basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix * Patients with a systemic fungal, bacterial, viral, or other infection not controlled * Any condition which, in the opinion of the investigator, would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Tolerability of JVRS-100 | Day 30 of cycle #1 | Toxicities will be assessed on day 30 of cycle 1. Establish dose limiting toxicity and a maximum tolerated dose recommended Phase 2 dose. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Define parameters of immune activation after JVRS-100 therapy. | Day 30 of cycle #1 | Activation of peripheral blood cells including T-cell subsets, CD4+ and CD8+ cells, B-cells, and NK cells will be studied for activation markers including cell surface phenotypic changes, and expression of intracellular cytokines. Changes in circulating cytokine concentrations will be studied, as will functional properties of circulating immune effector and activating cells. |
Countries
United States
Outcome results
None listed